Researchers have made a groundbreaking advancement in the treatment of type 1 diabetes by 3D printing devices made of insulin-producing cells. This innovative approach could potentially offer a long-term solution for individuals with type 1 diabetes, allowing them to produce their own insulin without the need for invasive surgery.
Individuals with type 1 diabetes face the challenge of not being able to produce enough insulin to regulate their blood sugar levels. As a result, they must constantly manage their condition through injections and dietary restrictions. One common treatment option involves transplanting human islets, which are clusters of insulin-producing cells found in the pancreas, from donors. However, this method requires invasive surgery similar to an organ transplant.
According to Quentin Perrier from the Wake Forest Institute for Regenerative Medicine in North Carolina, the current practice involves injecting human islets into the liver through the portal vein. Unfortunately, approximately half of the transplanted islets lose their functionality quickly, necessitating multiple transplantations to achieve the desired therapeutic outcome.
By placing the islets directly under the skin, the need for invasive surgery could be minimized, reducing stress and inflammation that can limit the functional lifespan of the cells. Adam Feinberg from Carnegie Mellon University and FluidForm Bio in Massachusetts explains that a higher density of islets would require smaller devices to be implanted in patients, making the process less invasive.
To achieve this high density, researchers have developed a technique using a “bioink” made from human pancreatic tissue and alginate, a seaweed-derived carbohydrate. Live insulin-producing cells are incorporated into this material, which is then 3D printed into a porous grid structure designed to promote the growth of new blood vessels around and through the device.
In laboratory experiments, this method has shown promising results, with approximately 90% of the islet cells surviving and functioning for up to three weeks. The next step is to validate these findings in living organisms, a challenge that researchers are actively pursuing.
Feinberg and his team have also successfully 3D printed islets using a different approach, incorporating cells and collagen into a hydrogel polymer framework. In animal studies, these printed islets restored normal glucose control for up to six months, showcasing the potential of this technology for long-term diabetes management.
While the current techniques show great promise, both Perrier and Feinberg agree that the future of type 1 diabetes treatment lies in stem cell therapies. By utilizing stem cells in the 3D printing process, researchers believe they can address many of the challenges associated with current treatment methods and pave the way for more effective and personalized diabetes care.
